Poland strikes deal to produce Novavax COVID vaccine
Image by Shutterstock.com
Polish biotech firm Mabion has signed a preliminary agreement to manufacture Novavax's COVID-19 vaccine with financial support from a state-run fund, reported the Polish News Agency (PAP).
Konstantynów Łódzki, central Poland-based Mabion said it had signed a deal with the US company for the transfer of technology and technological trials in the manufacture of an antigen for Novavax's vaccine, which is yet to be approved by the EU's medical agency.
State-run PFR will provide Mabion with PLN 40 million (USD 11 million) in loans and equity so the company can double its production capacity.
On January 27, Novavax reported that the vaccine had tested 89.3% effective in preventing COVID-19 and was almost as effective in protecting against the more infectious U.K. variant. Novavax is currently carrying out phase III clinical trials of its preparation.
ADVERTISEMENT
Mapei Targets 6% Higher Revenue This Year
Parliament Negates Mandatory Membership in MOK
Magyar Suzuki to Start Dual Training Courses
Budapest Leaders Unveil Plans to Scale Back Traffic on Thoro...
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
